目的 探讨尼达尼布联合奥美拉唑、莫沙必利的抗反流与抗纤维化联合方案对特发性肺纤维化患者肺功能、血气指标的改善作用及临床价值。方法 采用前瞻性队列研究,选取本院呼吸内科2021年1月—2023年1月就诊的96例特发性肺纤维化患者,选择随机数字表法分为常规组(n=48)和联合组(n=48),常规组予尼达尼布单药抗纤维化治疗,联合组在常规组基础上联用奥美拉唑和莫沙必利抗反流治疗,两组均持续治疗12个月。比较两组治疗前及治疗3、6、9、12个月的肺功能指标,包括一氧化碳弥散量(diffusing capacity of the lung for carbon monoxide,DLCO)、第一秒用力呼气容积(forced expiratory volume in one second,FEV1)、用力肺活量(forced vital capacity,FVC),以及血气指标,包括动脉血氧饱和度(arterial oxygen saturation,SaO2)、动脉血氧分压(arterial partial pressure of oxygen,PaO2)、动脉血二氧化碳分压(arterial partial pressure of carbon dioxide,PaCO2);采用改良版英国医学研究委员会呼吸困难量表(modified medical research council dyspnea scale,mMRC)、圣乔治呼吸问卷(St. George's respiratory questionnaire,SGRQ)评估治疗6、12个月的生活质量;随访24个月并统计急性加重频率。结果 联合组治疗3、6、9、12个月的DLCO、FVC均显著高于常规组同期(P<0.05)。联合组治疗各时间点SaO2、PaO2均高于常规组,PaCO2低于常规组(P<0.05)。联合组治疗6、12个月的mMRC评分、SGRQ评分均优于常规组同期(P<0.05)。联合组治疗12个月急性加重率为12.50%,随访24个月急性加重率为20.83%,分别低于常规组的31.25%和52.08%(P<0.05)。结论 抗反流治疗联合抗纤维化药物可显著改善特发性肺纤维化患者的肺功能、血气指标和生活质量,并降低急性加重频率。
Abstract
Objective To investigate the improvement effect and clinical value of the anti-reflux and anti-fibrotic combination regimen of nintedanib combined with omeprazole and mosapride on lung function and blood gas indexes in patients with idiopathic pulmonary fibrosis (IPF). Methods The conventional group was given nintedanib monotherapy for anti-fibrosis, and the combination group was combined with omeprazole + mosapride for anti-reflux treatment on the basis of the conventional group. Both groups were treated for 12 consecutive months. The lung function indexes[diffusing capacity for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC) ]and blood gas indexes[arterial oxygen saturation (SaO2), arterial partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2) ]of the two groups before treatment and at 3, 6, 9 and 12 months after treatment were detected. The quality of life at 6 and 12 months after treatment was evaluated by modified Medical Research Council (mMRC) and St. George's Respiratory Questionnaire (SGRQ). The frequency of acute exacerbations was counted during 24 months of follow-up. Results The DLCO, FEV1 and FVC of the combination group at 3, 6, 9 and 12 months after treatment were significantly higher than those of the conventional group during the same period (P<0.05). The SaO2 and PaO2 of the combination group at each time point of treatment were higher than those of the conventional group, and PaCO2 was lower than that of the conventional group (P<0.05). The mMRC scores and SGRQ scores of the combination group at 6 and 12 months after treatment were better than those of the conventional group during the same period (P<0.05). The acute exacerbation rate of the combination group was 12.50% at 12 months after treatment and 20.83% at 24 months of follow-up, which were lower than 31.25% and 52.08% in the conventional group (P<0.05). Conclusion Anti-reflux therapy combined with anti-fibrotic medications significantly improves pulmonary function, gas exchange parameters, and quality of life in patients with IPF and reduces the frequency of acute exacerbations.
关键词
特发性肺纤维化 /
抗反流治疗 /
抗纤维化药物 /
临床疗效
Key words
idiopathic pulmonary fibrosis /
anti-reflux therapy /
anti-fibrotic medications /
pulmonary function
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 白君, 陈珠妮, 叶景焕, 等. 双氢青蒿素对小鼠肺纤维化的影响及作用机制[J]. 中南医学科学杂志, 2023, 51(6): 848-852.
[2] SPAGNOLO P, DISTLER O, RYERSON CJ, et al.Mechanisms of progressive fibrosis in connective tissue disease (CTD) -associated interstitial lung diseases[J]. Ann Rheum Dis, 2021, 80(2): 143-150.
[3] 李蒙, 张静静, 李向南, 等. 十二指肠结扎对大鼠胃食管反流及博莱霉素肺纤维化的影响[J]. 中华医学杂志, 2021, 101(21): 1598-1605.
[4] AMATI F, STAINER A, POLELLI V, et al.Efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review[J]. Int J Mol Sci, 2023, 24(9): 7849.
[5] 黄丽惠, 王喆, 刘晓菊, 等. 特发性肺纤维化诊断方法研究进展[J]. 国际呼吸杂志, 2023, 43(11): 1333-1337.
[6] 吴宣谕, 肖祥, 陈梦秋, 等. “聚于胃, 关于肺”视角下探索麦门冬汤治疗胃食管反流病与特发性肺纤维化共病机制[J]. 中草药, 2025, 56(6): 2052-2065.
[7] WU S, YIN L, HAN K, et al.NAT10 accelerates pulmonary fibrosis through N4-acetylated TGFB1-initiated epithelial-to-mesenchymal transition upon ambient fine particulate matter exposure[J]. Environ Pollut, 2023, 322: 121149.
[8] CORTE TJ, BEHR J, COTTIN V, et al.Efficacy and safety of admilparant, an LPA1 antagonist, in pulmonary fibrosis: a phase 2 randomized clinical trial[J]. Am J Respir Crit Care Med, 2025, 211(2): 230-238.
[9] 李晓雯, 潘玲, 叶欣鑫, 等. 特发性肺纤维化合并胃食管反流的研究进展[J]. 中国医学创新, 2023, 20(25): 185-188.
[10] 吕昆明, 王沙沙, 万军, 等. 胃食管反流病与特发性肺纤维化关系的研究进展[J]. 中华胃肠内镜电子杂志, 2023, 10(2): 121-124.
[11] CHEN P, XIE L, MA L, et al.Prediction and analysis of genetic effect in idiopathic pulmonary fibrosis and gastroesophageal reflux disease[J]. IET Syst Biol, 2023, 17(6): 352-365.
[12] 王帅, 王亚文, 邹永祎, 等. 尼达尼布治疗特发性肺纤维化92例对肺功能和肺纤维化指标的影响及不良反应分析[J]. 安徽医药, 2023, 27(4): 826-829.
[13] 汪泓, 刘兆云, 曹中保. 替普瑞酮辅助奥美拉唑以及莫沙必利对反流性食管炎患者的临床治疗效果研究[J]. 实用药物与临床, 2022, 25(2): 144-147.
[14] YANG M, DONG J, AN J, et al.Effect of anti-reflux therapy on pulmonary function in idiopathic pulmonary fibrosis: a systematic review and meta-analysis[J]. J Thorac Dis, 2021, 13(10): 5776-5787.
[15] BLOEM AEM, MOSTARD RLM, STOOT N, et al.Patient activation for self-management in patients with idiopathic pulmonary fibrosis or sarcoidosis[J]. Respiration, 2022, 101(1): 76-83.
[16] 杨东明, 聂建军, 任蔚, 等. 尼达尼布联合汉防己甲素治疗结缔组织病相关肺间质纤维化患者的临床研究[J]. 中国临床药理学杂志, 2024, 40(19): 2781-2785.
[17] REYNOLDS CJ, DEL GRECO MF, ALLEN RJ, et al.The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study[J]. Eur Respir J, 2023, 61(5): 2201585.
[18] 唐晓媛, 曾省都. 奥美拉唑联合莫沙必利治疗特发性肺纤维化的疗效[J]. 深圳中西医结合杂志, 2019, 29(24): 97-98.
[19] 周璇, 谢莉, 邹娟. 尼达尼布对特发性肺纤维化肺功能, 肺纤维化程度及PDGF, PGE2, TGF-β1的影响[J]. 中华肺部疾病杂志电子版, 2024, 17(3): 368-372.
基金
邢台市重点研发课题 “抗反流治疗对特发性肺纤维化患者远期影响的临床研究”(2022ZC116)